Updated 10 August 2026. Regulatory status current as of this date.

Most approved peptide medicines are legal when prescribed appropriately. But wellness and lifestyle peptides such as BPC-157, TB-500 and MOTS-c remain unapproved and unproven; the FDA’s July 2026 advisory vote did not make them approved or immediately legal to compound. UK rules depend partly on how products are sold and the claims made for them.

---

On 23 and 24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee considered seven peptides and recommended six of them for the 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.

Emideltide, also known as DSIP, was not recommended. Five further peptides: GHK-Cu, Melanotan II, cathelicidin (LL-37), dihexa acetate and PEG-MGF, are due to be considered before the end of February 2027.

Within days the recommendation was being reported as an approval. That’s not an accurate characterisation and four things about it are being consistently missed or downplayed.

The votes were close. BPC-157, KPV and TB-500 each passed 8–6 with one abstention. MOTS-c passed 7–5 with two abstentions. Emideltide failed on a 7–6 split. The participating members divided narrowly on every substance considered.

The FDA’s own scientists were against all of it. Agency career reviewers uniformly opposed adding any of the seven substances, finding the available studies short in duration, small in sample size and insufficient to establish safety or effectiveness. On BPC-157 the review found a lack of evidence of effectiveness for the proposed indication of ulcerative colitis, and described the substance as not well characterised. On TB-500, reviewers could not find any human studies using the compound at all. The committee voted for these six over the objections of the people who had read the files.

The recommendation is not binding. The committee advises; the FDA decides, and it is under no obligation to follow. Before any of these substances can legally be compounded the agency has to complete formal notice-and-comment rulemaking — proposed rule, comment period, final rule — a process that routinely runs beyond a year. The law firm Buchanan Ingersoll & Rooney put it this way in its own client note: “the legal landscape for peptides has not changed”, and pharmacies “should not interpret the committee’s recommendations as authorization to begin compounding”.

Nothing is being restored. This is the detail almost every report we have read gets wrong, including some written by pharmacists. None of these substances has ever been formally added to the 503A Bulks List. Some were previously compounded under the FDA’s interim enforcement policy before being moved into Category 2 in 2023. So the July vote is not the reversal of a ban on something previously allowed.

And none of it was a verdict on whether the peptides work. The PCAC considers whether a substance is suitable for pharmacy compounding. That is a question about manufacturing, quality and clinical need, not a finding that a peptide produces a meaningful effect in humans.

We put that to Dr Dan Reardon, an NHS A&E doctor with a specialist interest in metabolic health. “Nothing changed in terms of evidence,” he says. “The evidence base remains the same. It was pretty much predicted this was going to happen anyway. I had a meeting with a compounding pharmacy not long ago and they told me they were already getting prepared to compound some of these peptides, because they were just aware this was going to happen. Nothing changed on the 24th of July. This is months and months of people knowing what was probably going to happen.” 

On why it happened now, Reardon points at politics rather than data, a view shared by much of the US coverage, which has framed the vote throughout as a push by health secretary Robert F. Kennedy Jr to widen peptide access.

“I think it’s the state of US politics now. People like RFK have been able to push things through off the back of enough people saying it might be a good idea,” Dr Reardon said.

Two committee members said something similar. Dr Elizabeth Rebello of MD Anderson: “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science.” Rita Jew, president of the Institute for Safe Medication Practices, called the decision “really alarming” given the state of the clinical evidence. Members with academic backgrounds mostly voted against; members with peptide industry experience mostly voted in favour.

What peptides did the FDA committee review?

The FDA committee voted on seven peptides. Not one of them was close to unanimous and there is no change of legal status in either the US or the UK. Here is where each of them actually stands, on both sides of the Atlantic.

Peptide	PCAC vote, 23–24 July 2026	US status now	UK status now
BPC-157	Recommended — 8–6, one abstention	Not legal to compound. Rulemaking not begun.	No marketing authorisation. Named in the MHRA inquiry into UK clinics.
KPV	Recommended — 8–6, one abstention	Not legal to compound. Rulemaking not begun.	No marketing authorisation. A regulated medicine if sold with medicinal claims.
TB-500	Recommended — 8–6, one abstention	Not legal to compound. Rulemaking not begun.	No marketing authorisation. A regulated medicine if sold with medicinal claims.
MOTS-c	Recommended — 7–5, two abstentions	Not legal to compound. Rulemaking not begun.	No marketing authorisation. Reported as named in the MHRA inquiry.
Epitalon	Recommended — similarly tight margin	Not legal to compound. Rulemaking not begun.	No marketing authorisation. A regulated medicine if sold with medicinal claims.
Semax	Recommended — similarly tight margin	Not legal to compound. Rulemaking not begun.	No marketing authorisation. A regulated medicine if sold with medicinal claims.
Emideltide (DSIP)	Not recommended — failed, 7–6, one abstention	Remains effectively prohibited.	No marketing authorisation. A regulated medicine if sold with medicinal claims.

Which peptides are approved, and which are not?

Most of the confusion in this subject comes from a blanket use of the word “peptide”. Insulin is a peptide. So is semaglutide. So is the unlabelled vial of BPC-157 posted from a warehouse. They belong to the same chemical class and to entirely different legal and evidential worlds.

Peptide	Sold as	Licensed for	Status
Insulin	many brands	Diabetes	Licensed for decades. Prescription only, both territories
Semaglutide	Ozempic, Wegovy	Type 2 diabetes; weight management	Prescription only, both territories
Tirzepatide	Mounjaro, Zepbound	Type 2 diabetes; weight management	Prescription only, both territories
Liraglutide	Victoza, Saxenda	Type 2 diabetes; weight management	Prescription only, both territories
Retatrutide	no brand yet	Under trial for weight management	Not approved anywhere. Phase III programme ongoing.
BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax	sold online as “research chemicals”	Nothing. No licensed indication.	No authorisation in either territory.
CJC-1295, Ipamorelin	sold online as “research chemicals”	Nothing. No licensed indication.	No authorisation. Not before the PCAC in July.

There is a pattern and it answers the question most people are really asking. Every peptide with a licence has one for a specific condition, arrived at through trials, and is available only on prescription. Every peptide sold direct to the public online has no licence for anything. There is no middle category.

Does the FDA vote mean these peptides work?

No. But it does not follow that the vote is meaningless. Compounding rules govern how a substance is made, not whether it does anything. Reardon’s argument is that getting the manufacturing right is the precondition for ever finding out.

“The importance of these decisions on compounding is that theoretically it should allow these peptides to be made at a good enough quality that they could go into much better standards of research,” he says. “You’re also mitigating the risk of major problems with purity and with what these peptides actually contain. But it’s the same problem: the lack of robust human studies.” 

So the real position is slightly different to the one that either camp is arguing. The July vote does not make BPC-157 effective, and it does not make it legal. What it may eventually do is make it consistent, and a consistent compound is one you can run a trial on.

“This isn’t me being sceptical about whether they’re useful or not,” says Reardon. “It’s purely that if you’re injecting something into your body, you really want to make sure there’s good quality data and that the money you’re spending means it’s actually going to have an effect.” 

---

Most peptides being sold in the wellness market today have not been through the clinical trials required to prove they produce a meaningful effect in humans. A small number (notably approved GLP-1 medicines) have done that work and represent genuine breakthroughs. Eli Lilly’s investigational retatrutide is beginning to produce Phase III evidence of similarly significant effects, but remains unapproved.

What are peptides?

A peptide is a short chain of amino acids; essentially a small fragment of a protein. Peptides function as signalling molecules in the body, telling cells what to do. Insulin is a peptide. So is GLP-1, the gut hormone behind the global weight-loss drug revolution. Doctors have been prescribing peptides for roughly a century. Insulin was first isolated in 1921.

This last point matters because it directly contradicts the framing that has powered the current investment cycle.

“People talk about peptides like they’re new. That’s where the nonsense begins,” says Reardon. His perspective on the peptide boom isn’t theoretical. In an average week he treats multiple patients presenting with complications from unregulated injectable use, infections from contaminated compounds, cardiac events from stacked stimulants, steroid-related complications in patients as young as 15. Almost none of those are peptide cases, and he is careful about the distinction. Asked directly in August 2026 whether he was seeing harm from the peptides discussed here, he said he was not.

He has also spent more than a decade following the performance pharmacology space, including as a former contributor to Muscle and Fitness and Flex magazines.

That combination, clinical exposure to what’s actually being injected, plus deep knowledge of the marketing apparatus selling it, gives him a vantage point most commentators on the peptide boom simply don’t have.

“Insulin is a peptide hormone,” he says. “GLP-1, which everyone talks about now, was discovered in 1982. We’ve been using peptides in medicine for years. There’s nothing new about them. What’s happened is some peptides partially went through the process of clinical trials and ultimately they failed. But there was a process of discovery, and some of those failed products have ended up in the peptide markets.”

The pitch decks driving the current capital cycle tend to be light on this backstory. Capital, as a rule, prefers novelty.

Why GLP-1 is the wrong comparison for most peptides on the market

The reason GLP-1 drugs like Ozempic, Wegovy and Mounjaro reshaped global metabolic health is not because GLP-1 was a recent discovery. It’s because the molecule went through forty years of pharmaceutical development before it reached the form consumers know today.

GLP-1 was identified in the early 1980s. The first commercial product, exenatide, used in diabetes, reached the market around 2005. The current generation of weight-loss injectables took another two decades on top of that.

Reardon explains the journey: “Initially they discovered GLP-1 and GLP-2. Eventually they realised that GLP-1 had an effect on appetite, increased the amount of insulin you released, and suppressed glucagon. But from that point to today, it’s been 40 years. And the physiological effects of these GLP-1 agonists or analogues, whatever you want to call them, is unbelievable. It’s absolutely unbelievable in terms of the physiological effect.”

Four decades of trials. Failures. Refinement. Safety work. Regulatory review. That is what it takes for a signalling molecule to become a drug that actually works in humans at scale.

Most of the peptides currently being marketed as wellness products have not done that work. Some failed in clinical trials and ended up on the grey market regardless. Most are being marketed on the basis that they affect a particular biological pathway, which is a very different claim from producing a measurable, useful outcome in a real person.

The core problem: affecting a pathway isn’t the same as producing a result

This is the conceptual gap most peptide marketing relies on the consumer not noticing. A common claim made for several popular peptides is that they increase growth hormone or IGF-1 levels. That claim is, in many cases, technically accurate. The problem is that elevated growth hormone does not, on its own, produce the outcomes consumers are buying these products for.

“You can raise a hormone,” Reardon says, “but that doesn’t mean anything useful happens. A lot of bodybuilders know that an elevated growth hormone doesn’t necessarily do anything. There might be a small number of people that do get some benefits, a reduction in joint pain, increased tendon strength, ligament strength, but it’s quite anecdotal.”

He puts the test more simply still: “If raising growth hormone was genuinely beneficial, we’d all be injecting growth hormone.”

The same logic applies to peptides marketed for cellular energy, mitochondrial function, telomere length and cognitive performance. The signalling pathway may exist. The molecule may even bind to the right receptor. But whether any of that translates into a measurable improvement in a human being’s day-to-day function is, in most cases, unproven.

The specific peptides being sold and what the evidence actually shows

MOTS-c

One of the most heavily marketed wellness peptides on the market and one of the seven peptides scheduled for FDA advisory committee review in July 2026. The pitch is that MOTS-c activates AMPK signalling pathways and improves cellular energy expenditure.

“It’s a real peptide,” Reardon confirms. “MOTS-c is something that gets produced as a stress response in the mitochondria. So it exists, no one’s disputing that. But the question is, if you inject it into yourself, does that necessarily mean that you’re going to get this upregulation in the mitochondria? There is absolutely no evidence whatsoever that that’s the case. There is no evidence in humans of the contrary to that.”

His verdict: that it is unproven rather than proven dangerous, which is not the same as safe. FDA reviewers found the studies on all seven peptides short in duration, small in sample size and insufficient to establish either safety or effectiveness. On that basis there is no good evidence MOTS-c causes harm, and none that it does not.

TB-500

Thymosin beta-4 has been through controlled ophthalmic trials — phase II in dry eye and phase III in neurotrophic keratopathy — a long way from the tissue-repair claims made for TB-500 in fitness marketing. On the composition problem, the FDA’s associate director Russell Wesdyk told the July committee, of substances of this kind: “There’s no way to know what the substance actually is, was or will be tomorrow.”

“There is evidence that thymosin beta-4 can improve ocular tissue repair,” Reardon says. “But that’s pretty much it. There’s no other evidence that it does anything else. And then TB-500 has been sold in these fragmented forms, but there’s no evidence it does anything.”

Growth Hormone Releasing Peptides (CJC-1295, Ipamorelin, Sermorelin)

These peptides do affect growth hormone release. The clinical question is whether the resulting elevation produces any meaningful physiological outcome.

“If we’re just boosting growth hormone but not necessarily getting any measurable outcome in terms of improved muscle strength, improved recovery, reduced joint inflammation, reduced joint pain, improved mobility, flexibility, if you’re not getting any of that, then there’s no benefit to actually taking it in the first place.”

GLP-1 (Semaglutide, Tirzepatide)

The exception that proves the rule. Forty years of development. Phase 3 clinical evidence. Marketing authorisation. Demonstrable, dramatic, repeatable outcomes in real patients.

This is what the rest of the category is being priced against. Almost none of it has earned the comparison.

The one peptide on the horizon that might genuinely matter

Reardon is not categorically pessimistic about the future of the category. There is one specific candidate he flags as genuinely significant: retatrutide, a next-generation drug from Eli Lilly that has now produced its first major phase 3 readout.

Retatrutide is a triple agonist, acting on the GIP, GLP-1 and glucagon receptors simultaneously. On 19 March 2026, Eli Lilly announced topline results from its TRANSCEND-T2D-1 phase 3 trial in adults with type 2 diabetes. Participants taking the highest dose achieved an average A1C reduction of up to 2.0% and lost an average of 36.6 lbs (16.8% of body weight) at 40 weeks. Critically, no weight loss plateau was observed — participants were still losing weight at the end of the trial. (Source: Eli Lilly investor announcement.)

An earlier phase 3 readout from the TRIUMPH-4 trial in December 2025, in adults with obesity and knee osteoarthritis, showed weight loss of up to 71.2 lbs alongside meaningful reductions in osteoarthritis pain.

Reardon highlighted what makes retatrutide scientifically distinct before the data dropped:

“I think retatrutide is really interesting. And it’s not necessarily because of the GLP-1 or GIP part, though that’s unbelievable in itself, it’s the glucagon agonist piece. It’s this idea that we can get improvements in cellular energy expenditure.”

The implication is significant. GLP-1 drugs have transformed weight management primarily by suppressing appetite. Retatrutide may be able to do something different: change the relationship between muscle tissue and energy expenditure, helping people who have historically struggled to build a sustainable relationship with exercise actually feel and benefit from physical activity.

“That might enable them to get the benefits from exercise, contract muscles in the right way, utilise and burn fat in the right way, burn carbs in the right way, see improvements in liver health. That might make this something that’s really, really interesting and potentially life-changing for some people.”

But, and this is the point, retatrutide got there the long way. It’s a regulated pharmaceutical that has been through full clinical trials with results
announced by Lilly in March 2026 and presented at the American Diabetes Association’s 2026 scientific sessions. They have not yet appeared in a peer-reviewed journal, which is normal at this stage. (Source: Eli Lilly retatrutide overview.)

Why the hype persists despite the thin evidence

If the human evidence base for most wellness peptides is so thin, why is the market so confident?

Reardon’s answer is that peptides have something most consumer health products don’t: a genuinely compelling narrative.

“The thing with peptides is, it’s a great story. And you can make it make sense. You can listen to people, really animated people, who give these great stories about why these things are so fantastic and all the benefits that you can have from them.”

Peptides sound scientific. They sound precise. They sound like the future. The mechanism explanations are plausible-sounding enough to satisfy a curious consumer who hasn’t read the trial data, which is most consumers.

The doctors actively prescribing peptides in the UK, Reardon notes, tend to come from a particular professional background:

“Classically the doctors that have been injecting Botox and fillers into people. Where their barrier to intervention from the perspective of wellness is quite low and not necessarily always well understood in the long term.”

The safety question nobody is talking about

Beyond the efficacy question, there is a separate and more concerning issue: what consumers are actually injecting when they buy peptides through unregulated channels.

“Compounding facilities are getting closed around the world left, right and centre,” Reardon says. “We don’t have that same sort of rigour on overall safety. We should know where the product’s coming from, how it’s been manufactured, how it’s been imported — just some of the basic stuff.”

In an unregulated market, the consumer has no reliable way to verify that the vial they’ve purchased contains what it claims to contain, in the dosage stated, free of contaminants. The FDA review is, in part, an attempt to address this. The agency has historically restricted these compounds because of concerns about immunogenicity, toxicity, impurity risk and inadequate human clinical evidence – concerns that have not gone away just because the political winds have shifted.

Until the regulatory process concludes, the safety floor under the consumer peptide market is significantly lower than buyers tend to assume.

Are peptides safe and legal?

Legally, in the US: no clearer than in April, and not legal to compound. The July recommendation moves six peptides closer to a status they have never held, and the rulemaking that would grant it has not begun.

In the UK the position is different, it is where most readers of this piece live, and it does not depend on the FDA at all. That is the next section.

On safety, the answer does not follow from the legal one at all, and that is the distinction most coverage collapses. A substance can be permitted and unproven at the same time. What the July vote establishes is that a narrow majority of one committee considered these six suitable for pharmacy compounding. It establishes nothing about what happens when someone buys the same compound from an unregulated seller online, at an unverified dose and unverified purity. Reardon’s own position is unchanged by the vote:

“I would never recommend anybody uses these unapproved peptides, irrespective of whether they might work,” says Dr Reardon. “You don’t know where they’re coming from, you don’t know what they contain, you don’t know the risks. If somebody tells me they’re using peptides, I stand by my position: you probably shouldn’t be.” 

“As the evidence changes, and as the places they come from change so you can be assured they’re from high-grade manufacturing — if there’s then robust human evidence, I will change my opinion. At this stage it’s just not something I would recommend.” 

The specific risks are not vague, and they are not ours. They are the ones the FDA itself set out when it restricted these substances in the first place, and the ones its reviewers repeated in July.

Impurities and immunogenicity — the immune system reacting to the injected compound — were among the grounds FDA gave in September 2023 for restricting this group, along with aggregation risk and absent human safety data.

Not knowing what the substance is. FDA reviewers described BPC-157 as not well characterised, which makes quality standards impossible to set. On compounds of the TB-500 type, the agency’s associate director put it as bluntly as it can be put: “There’s no way to know what the substance actually is, was or will be tomorrow.”

Unknown fragments. Reardon’s point about TB-500 is a specific instance of the same problem: a fragment preparation whose fragments are not specified is not one substance but a family of them.

Unverified dose and purity. None of the above concerns a regulated pharmacy. All of it concerns a vial bought from an unregulated seller, which is how almost everyone reading this would actually obtain these compounds.

Are peptides legal in the UK?

Not in the sense most sellers imply. No peptide the FDA committee considered in July holds a UK marketing authorisation, so none of them can be sold in Britain as a licensed medicine. What decides their legal status is not the compound. It is the claim made for it.

The MHRA’s test is intended purpose. Peptide products may be sold as cosmetics, supplements or medicines, and the agency has said they “fall under different regulatory frameworks” depending on what they are sold for, with medicine status decided case by case. The line that matters if you are buying from a clinic:

“If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012.”  MHRA

Does “research use only” make it legal? No, and this is the most useful thing on the page.

Nearly every UK site selling these compounds labels them for research or laboratory use only. Set that against what the regulator says about the label:

“We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations.”  MHRA

The phrase is not a legal shield. It is a form of words the MHRA has said publicly it looks straight through.

The regulator has also drawn the boundary of its own remit: “Not all peptides fall under MHRA’s remit, for example, many peptides are sold for body-building purposes and in the absence of medicinal claims, these would not be considered medicines.” A vial sold with no claim attached may sit outside the framework altogether, which is exactly why so much of the UK market is labelled for research rather than for people.

None of this is theoretical. In April 2026 a Guardian investigation found UK clinics offering experimental peptides while advertising claims about their benefits, and the MHRA opened an inquiry, saying it “will take action against clinics which are identified as breaching the legal requirements”. Reported enforcement options run from warnings to product seizures. Compounds named in that reporting include Cortexin, thymosin alpha-1 and BPC-157.

That last name is the reason this page needed rewriting rather than patching. BPC-157 is simultaneously one of the six peptides an FDA advisory committee recommended for compounding in July, and one of the compounds a UK clinic was reported in April for advertising. The same molecule is moving toward regulated availability in one country while drawing regulatory attention in another. Nothing decided in Maryland in July changes what a clinic in London may lawfully tell you about it.

Are people in the UK being harmed by peptides bought online?

Reardon is not yet seeing them in significant numbers in his own A&E work. That cannot tell us what is happening across Britain, but it suggests the problem has not yet reached the visibility of the earlier black-market GLP-1 wave.

“I don’t think use in the UK is widespread enough for me to have legitimate concerns that all of a sudden in A&E I’m going to start seeing people coming in with problems as a result of peptides,” says Dr Reardon. “When the GLP-1s first came out on a large scale we were seeing a lot of black-market GLP-1 availability, and then people coming in with problems. I haven’t seen anybody coming into A&E with black-market GLP-1 related problems as we did two or three years ago. The black market has largely calmed down there.” 

He does expect that to change, and he is specific about the trigger, which is not the July vote.

“If lifestyle peptides became readily available on prescription, that’s when I think we’d start to see more of the black-market type problems, because it would raise people’s exposure to the concept,” says Dr Reardon. “But I don’t think that’s happened yet, and I don’t think it’s necessarily likely to happen any time soon.” 

The risk he does describe is not a hospital admission. It is spending money and taking an injection instead of doing the thing that would have worked.

“My concern would be people using peptides thinking this is going to be some miraculous cure to a problem,” says Dr Reardon. “If someone is overweight and they’re injecting BPC-157 because they think it’s going to fix their gut, I think they’re being misled. There are a lot of other things you’d do first. The effects of a [lifestyle] peptide are never going to be as good as the effects of exercise and eating the right sorts of foods in moderation.” 

What people are actually injecting (and what they think they’re injecting)

Here is the part of the peptide boom that almost no one writing about it from the investor side has had to deal with: what arrives in the vial is frequently not what’s printed on the label.

Reardon describes the gap between consumer perception and clinical reality bluntly.

“People assume that because something has a scientific name and comes in a sealed vial, it’s been quality-controlled. In a regulated pharmacy, that’s true. In the grey market, which is where most of these peptides are bought, it’s not.”

The structural problem is that compounding facilities producing peptides for international sale have been closing or being shut down across multiple jurisdictions over the past two years, including in Asia, Eastern Europe and parts of the United States. The supply chain has fragmented. New entrants have moved in. Quality control has not always followed.

There is currently no requirement for grey-market peptide vendors to test or disclose any of this. The buyer has no realistic way to verify what they’ve injected until something goes wrong.

This is the safety floor under most of the consumer peptide market today. It is also the reason that even clinicians who are open to peptide therapy are insistent that the only acceptable route is a regulated pharmacy operating under physician oversight.

“It’s not the molecule I’m worried about with most of these peptides,” Reardon says. “It’s everything that comes with it when there’s no regulation in the supply chain.”

Are peptides the next GLP-1?

On the evidence so far, no, and the comparison is the problem rather than the point.

“In the UK people are getting more familiar with the concept of a peptide, but that’s really been driven by the GLP-1s,” says Dr Reardon. “The GLP-1s are an example of a peptide that has quite dramatic effects. Those effects are not seen in the other peptides, including the ones now being compounded. The risk is that when people equate peptide with GLP-1, and you tell them this one helps you lose fat, this one strips visceral fat, this one improves energy, they might just equate them all in the same way.” 

Which is a fair description of how the July vote was read. One class of drug with a large, well-documented effect has made the word “peptide” sound like a category of things that work. Six unrelated compounds then cleared a committee on narrow votes, against the advice of the agency’s own reviewers, and were reported as approved.